Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vaccinex's average Accounts Receivable for the
three
months ended in Dec. 2024 was $0.91 Mil. Vaccinex's Revenue for the
three
months ended in Dec. 2024 was $0.21 Mil.
Hence, Vaccinex's Days Sales Outstanding for the
three
months ended in Dec. 2024 was 390.49.
The historical rank and industry rank for Vaccinex's Days Sales Outstanding or its related term are showing as below:
VCNX's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.64 * Ranked among companies with meaningful Days Sales Outstanding only.
Vaccinex's Days Sales Outstanding
increased
from Dec. 2023 (0.00) to Dec. 2024 (390.49).
Vaccinex (OTCPK:VCNX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Vaccinex Days Sales Outstanding Related Terms
Vaccinex Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Vaccinex's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VCNX vs SXTP, PHGE, CPMV: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Vaccinex's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaccinex Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaccinex's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Vaccinex's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 390.49 mean?
Vaccinex (VCNX) has a Days Sales Outstanding of 390.49 as of Dec. 2024. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vaccinex and its competitors.
Is Vaccinex's Days Sales Outstanding too high?
Vaccinex's current Days Sales Outstanding is 390.49. The Biotechnology industry median Days Sales Outstanding is 68.64. Vaccinex's value of 390.49 is 468.9% above this industry median. Overall, Vaccinex has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaccinex's Days Sales Outstanding compare to SXTP and PHGE?
Vaccinex's Days Sales Outstanding of 390.49 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.64. Vaccinex's value of 390.49 is 468.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.64, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaccinex's current Days Sales Outstanding of 390.49 is 468.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Vaccinex and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaccinex's current Days Sales Outstanding is 390.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaccinex stock overvalued right now?
Vaccinex (VCNX) has a current Days Sales Outstanding of 390.49. The current Days Sales Outstanding is 390.49 and 468.9% above the Biotechnology industry median of 68.64. Vaccinex's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Vaccinex (VCNX), the current Days Sales Outstanding is 390.49 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vaccinex Inc is a clinical stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company operates and manages its business as one operating and reportable segment, which is the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. The firm has also developed a proprietary drug discovery platform, ActivMAb.
50GF Score
Get the complete analysis for VCNX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCNX has been successfully added to your 
